39.44

1.94% 0.75

After Hours: 39.70 0.26 +0.66%

Cogent Biosciences Inc (COGT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Cogent Biosciences Inc stock is traded at $39.44, with a volume of 1.77M. It is up +1.94% in the last 24 hours and up +27.14% over the past month. Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Previous Close:

$38.69

Open:

$38.87

24h Volume:

1.77M

Relative Volume:

0.73

Market Cap:

$6.74B

Revenue:

Net Income/Loss:

$-354.30M

P/E Ratio:

-15.63

EPS:

-2.5234

Net Cash Flow:

$-286.27M

1W Performance:

+1.81%

1M Performance:

+27.14%

6M Performance:

+13.40%

1Y Performance:

+420.32%

1-Day Range:

$38.10

$39.62

1-Week Range:

$37.81

$40.09

52-Week Range:

$8.80

$43.73

Cogent Biosciences Inc Stock (COGT) Company Profile

Name

Cogent Biosciences Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

617-945-5576

Address

275 WYMAN STREET, WALTHAM

Employee

258

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

COGT's Discussions on Twitter

Compare COGT vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
COGT Cogent Biosciences Inc	39.44	6.61B	0	-354.30M	-286.27M	-2.5234
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Resumed	Jefferies	Buy
Nov-10-25	Upgrade	Stifel	Hold → Buy
Nov-10-25	Upgrade	Wedbush	Neutral → Outperform
Oct-16-25	Initiated	Stifel	Hold
Sep-03-25	Initiated	Raymond James	Strong Buy
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Dec-11-24	Downgrade	Needham	Buy → Hold
Feb-26-24	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-08-24	Initiated	Citigroup	Buy
Dec-11-23	Downgrade	Wedbush	Outperform → Neutral
Dec-08-23	Initiated	JP Morgan	Overweight
Apr-28-23	Initiated	Robert W. Baird	Outperform
Mar-27-23	Resumed	H.C. Wainwright	Buy
Dec-14-22	Initiated	Needham	Buy
Jun-28-22	Initiated	Guggenheim	Buy
Oct-11-21	Initiated	H.C. Wainwright	Buy
Jun-09-21	Resumed	Jefferies	Buy
Dec-23-20	Initiated	Piper Sandler	Overweight
Oct-14-20	Initiated	Ladenburg Thalmann	Buy

View All

Cogent Biosciences Inc Stock (COGT) Latest News

Jul 01, 2026

COGTCogent Biosciences Inc Forecast, Target Price - Finviz

Jul 01, 2026

Jun 30, 2026

How (COGT) Movements Inform Risk Allocation Models - Stock Traders Daily

Jun 30, 2026

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Advanced Systemic Mastocytosis - Investing News Network

Jun 30, 2026

Cogent Biosciences Submits US FDA New Drug Application for Potential Mast Cell Disease Treatment - marketscreener.com

Jun 30, 2026

Cogent seeks FDA approval for rare blood disease drug - Stock Titan

Jun 30, 2026

Jun 29, 2026

Why Cogent Biosciences (COGT) Is Up 6.7% After Russell Index Removal Reshapes Its Investor Base - simplywall.st

Jun 29, 2026

Cogent Biosciences stock retreats after recent gains as bullish momentum consolidates - Traders Union

Jun 29, 2026

Cogent Biosciences stock edges lower with sideways action after Elevation Summit event - Traders Union

Jun 29, 2026

Cogent Biosciences, Inc.(NasdaqGS: COGT) dropped from Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026

Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 29, 2026

Cogent Biosciences, Inc. Actuals & Estimates (NASDAQ:COGT) - TradingView

Jun 29, 2026

Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Cogent Biosciences, Inc.(NasdaqGS: COGT) dropped from Russell Microcap Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Cogent Biosciences, Inc.(NasdaqGS: COGT) dropped from Russell 3000E Index - marketscreener.com

Jun 28, 2026

Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Ros Matthew - Moomoo

Jun 28, 2026

Jun 27, 2026

Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Shegog Todd - Moomoo

Jun 27, 2026

Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Robbins Andrew R - Moomoo

Jun 27, 2026

Jun 26, 2026

COGT Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Jun 24, 2026

Cogent (COGT) Presents Preclinical Data for Novel JAK2 Inhibitor CGT1145 at 2026 EHA Congress - Insider Monkey

Jun 24, 2026

Jun 22, 2026

Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market? - Yahoo Finance

Jun 22, 2026